Treatment
16
Table 1. Antimicrobial therapy for Staphylococcal and
Streptococcal SSTIs
a
(continued)
Disease Entity Antibiotic Adult Dosage
MRSA Vancomycin
Vancocin
®
, (generic)
30 mg/kg/d in 2 divided
doses IV
Linezolid
Zyvox
®
600 mg q12h IV or
600 mg bid PO
Clindamycin
Cleocin
®
, (generic)
600 mg q8h IV or
300-450 mg qid PO
Daptomycin
Cubicin
®
4 mg/kg q24h IV
Cearoline
Teflaro
®
600 mg bid IV
Doxycycline Vibramycin
®
,
minocycline Minocin
®
,
(generic)
100 mg bid PO
SMX-TMP
Bactrim
®
, Septra
®
, (generic)
One or two double-strength
tablets bid PO
Streptococcal skin
infections
Penicillin (generic) 2-4 million units q4-6h IV
Penicillin VK (generic) 250-500 mg q6h PO
Nafcillin (generic) 1-2 g q4-6h IV
Cefazolin (generic) 1 g q8h IV
Cephalexin Keflex
®
,
(generic)
500 mg q6h PO
Clindamycin
Cleocin
®
, (generic)
600-900 mg q8h IV
a
Tedizolid and dalbavancin (approved after publication of the 2014 guideline) are also effective
treatments of SSTI including those caused by MRSA.
Oritavancin (Orbactiv™) received approval by FDA for this indication prior to the IDSA's approval
of this guideline. It will be fully considered for inclusion by the panel the next time this guideline is
updated.
b
Doses listed are not appropriate for neonates. For neonatal doses, refer to Pickering LK, ed. Red Book:
Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of
Pediatrics; 2003.
